We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for bulevirtide (Gilead Sciences Pty Ltd)
Active ingredients
bulevirtide
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Bulevirtide is for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease
Therapeutic area
Infectious diseases